-+ 0.00%
-+ 0.00%
-+ 0.00%

Burning Rock's STELLA Shows 65.9% Sensitivity, 97.2% Specificity in Breast Lesion Study

PUBT·10/27/2026 02:53:02
Burning Rock's STELLA Shows 65.9% Sensitivity, 97.2% Specificity in Breast Lesion Study
  • Burning Rock Biotech presented STELLA breast lesion clinical validation results at the ESMO Congress on October 27, 2026.
  • The 516-patient PERCEIVE-BREAST study showed potential for STELLA to help distinguish malignant from benign breast lesions alongside conventional imaging.
  • Detection improved with disease stage; negative results alone cannot rule out malignancy, requiring follow-up imaging and pathological examination.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Burning Rock Biotech Ltd. published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.